N/A N=26 Immunotherapy of the Paraneoplastic Syndromes
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=68 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Phase 2 N=13 Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
Phase 2 N=93 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
Phase 2 N=30 Phase 2 Study of ONC201 in Neuroendocrine Tumors
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Phase 2 N=20 Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Locally Advanced Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma · Metastatic Paraganglioma
Primary: Objective Response Rate — 25 percentage of participants
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
N/A N=215 BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
Phase 2 N=60 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Neuroendocrine Tumor · Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate — 0.0 percentage of patients
Phase 2 N=23 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Neuroendocrine Tumors · Carcinoma, Small Cell Lung · Neuroendocrine Carcinoma
Primary: Phase 1: Maximum Tolerated Dose of PEN-221 and Recommended Phase 2a Dose (RP2D) — 18.0 mg
Phase 2 N=93 Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Neuroendocrine Tumor · Anaplastic Thyroid Cancer · Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 2; 2; 2 Participants
Phase 2 N=15 PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Overall Response as Determined by iRECIST — 1; 1; 3; 9 Participants
Phase 2 N=116 Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Phase 2 N=19 Cabozantinib and Nivolumab for Carcinoid Tumors
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=32 Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Phase 2 N=61 Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate (ORR) — 3; 7 Participants
Phase 2 N=105 Taxol Carboplatin and Erythropoetin
Ovarian Cancer
Primary: Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25% — 28.8 months
Phase 2 N=36 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Phase 2 N=25 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Paraganglioma · Pheochromocytoma
Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…
Phase 2 N=13 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Pancreatic Neuroendocrine Tumor G1 · Pancreatic Neuroendocrine Tumor G2 · Refractory Pancreatic Neuroendocrine Carcinoma
Primary: Overall Response Rate — 0 proportion of participants
Phase 1 N=10 Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
Lung Cancer
Primary: Confirmation of Tumor Targeting as Measured by the Number of Patients With Assessable Lesions Greater Than or Equal to 2 cm Measured by FDG-PET and SPECT Imaging. — 5; 5…
Phase 2 N=37 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
Phase 4 N=50 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
NeuroEndocrine Tumours
Primary: Assessment of Clinical Symptomatic Response — 77.8; 95.5; 87.5; 22.2 Percentage of Subjects — p==0.126
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 2 N=1,553 Studies of Elevated Parathyroid Activity
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants